Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
PURPOSE: To determine the early and late cumulative incidence of anthracycline-induced clinical heart failure (A-CHF) after anthracycline therapy in childhood and to identify associated risk factors. PATIENTS AND METHODS: The cumulative incidence of A-CHF and the risk factors of A-CHF were assessed in a cohort of 607 children who had been treated with anthracyclines between 1976 and 1996. For 96% of the cohort, we obtained the clinical status up to at least January 1997. The mean follow-up time was 6.3 years. RESULTS: The cumulative incidence of A-CHF was 2.8%, after a mean follow-up time of 6.3 years and a mean cumulative dose of anthracyclines of 301 mg/m 2. A cumulative dose of anthracycline higher than 300 mg/m 2 was associated with an increased risk of A-CHF (relative risk, 11.8; 95% confidence interval, 1.6 to 59.5) compared with a cumulative dose lower than 300 mg/m 2. The estimated risk of A-CHF increased with time after the start of anthracycline chemotherapy to 2% after 2 years and 5% after 15 years. CONCLUSION: Up to 5% of patients will develop A-CHF 15 years after treatment, and patients treated with a cumulative dose of anthracyclines higher than 300 mg/m 2 are at highest risk for A-CHF. This is thus a considerable and serious problem among these young patients. The findings reinforce the need for strategies for early detection of patients at risk for A-CHF and for the evaluation of other chemotherapeutic possibilities or cardioprotective agents in relation to the survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Cited by
Stewart, F. A., Akleyev, A. V., Hauer-Jensen, M., Hendry, J. H., Kleiman, N. J., MacVittie, T. J., Aleman, B. M., Edgar, A. B., Mabuchi, K., Muirhead, C. R., et al. (2012) · Annals of the ICRP · doi:10.1016/j.icrp.2012.02.001 · Cited by 1,604
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Medical Assessment of Adverse Health Outcomes in Long-term Survivors of Childhood Cancer
Geenen, M. M., Cardous-Ubbink, M. C., Kremer, L. C. M., van den Bos, C., van der Pal, H. J. H., Heinen, R. C., Jaspers, M. W. M., Koning, C. C. E., Oldenburger, F., Langeveld, N. E., et al. (2007) · JAMA · doi:10.1001/jama.297.24.2705 · Cited by 860
Self-citationLate cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.121 · Cited by 727
Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Möricke, A., Reiter, A., Zimmermann, M., Gadner, H., Stanulla, M., Dördelmann, M., Löning, L., Beier, R., Ludwig, W.-D., Ratei, R., et al. (2008) · Blood · doi:10.1182/blood-2007-09-112920 · Cited by 612
Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Petersen, E. J., Raemaekers, J. M. M., Kok, W. E. M., Aleman, B. M. P., & van Leeuwen, F. E. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1180 · Cited by 514
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Self-citationOeffinger, K. C., & Hudson, M. M. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.4.208 · Cited by 365
High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors
van der Pal, H. J., van Dalen, E. C., van Delden, E., van Dijk, I. W., Kok, W. E., Geskus, R. B., Sieswerda, E., Oldenburger, F., Koning, C. C., van Leeuwen, F. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4730 · Cited by 320
Self-citationvan Dalen, E. C., van der Pal, H. J. H., Kok, W. E. M., Caron, H. N., & Kremer, L. C. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.005 · Cited by 284
Self-citationShankar, S. M., Marina, N., Hudson, M. M., Hodgson, D. C., Adams, M. J., Landier, W., Bhatia, S., Meeske, K., Chen, M. H., Kinahan, K. E., et al. (2008) · Pediatrics · doi:10.1542/peds.2007-0575 · Cited by 283
Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., Brunham, L. R., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3374 · Cited by 278
Self-citationDifferent anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Self-citationGalper, S. L., Yu, J. B., Mauch, P. M., Strasser, J. F., Silver, B., LaCasce, A., Marcus, K. J., Stevenson, M. A., Chen, M. H., & Ng, A. K. (2011) · Blood · doi:10.1182/blood-2010-06-291328 · Cited by 253
Metadata
- Authors
- Kremer, L. C. M., van Dalen, E. C., Offringa, M., Ottenkamp, J., & Voûte, P. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-01-01
- Volume
- 19
- Issue
- 1
- Pages
- 191-196
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148209445
- Cited by
- 399
- References
- 17
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.